Benzinga | May 4, 2021 08:17AM EDT

Viiv Healthcare Initiates Rolling Submission Of New Drug Application With US FDA For Long-Acting Cabotegravir For Prevention Of HIV

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for investigational, long-acting, injectable cabotegravir for the prevention of HIV, also called pre-exposure prophylaxis, or PrEP.